Hisense Captures the Global Spotlight with Six EISA Awards for Image and Sound Excellence
DUBAI, UAE, Aug. 26, 2025 /PRNewswire/ — Hisense has reaffirmed its position as a global leader in picture and sound technology after winning six prestigious... Read more.
Brevan Howard and Lunate Announce Long-Term Strategic Partnership to Establish Investment Platform in Abu Dhabi
With an initial long-term commitment of USD 2 billion from Lunate, the platform will be domiciled in ADGM Partnership marks Lunate’s expansion into hedge funds,... Read more.
Jacobs Supports Landmark Marselis Tunnel Project in Denmark
Transformative infrastructure project to boost economic growth and improve urban spaces DALLAS, Aug. 26, 2025 /PRNewswire/ — Jacobs (NYSE: J) has been selected... Read more.
NVISAGE to Debut Portable Launch Monitor NEO-E at IFA 2025
VERNON HILLS, Ill., Aug. 26, 2025 /PRNewswire/ — NVISAGE Technologies, a U.S.-based innovator in golf technology solutions, will debut its newest portable... Read more.
Groundbreaking Research from LF AI & Data Reveals Open Source is Paramount for Global Sovereign AI
New report from LF AI & Data, LF Research, and Futurewei shows organizations are pursuing sovereign AI for greater data control, national security and localization... Read more.
Straatman acquires Kraaijeveld Winches to strengthen Dutch Maritime Industry
ZWIJNDRECHT, Netherlands, Aug. 26, 2025 /PRNewswire/ — Straatman (www.mfstraatman.com) is proud to announce the acquisition of Kraaijeveld Winches (www.safewinch.com),... Read more.
Gaotu Techedu Announces Second Quarter 2025 Unaudited Financial Results
BEIJING, Aug. 26, 2025 /PRNewswire/ — Gaotu Techedu Inc. (NYSE: GOTU) (“Gaotu” or the “Company”), a leading technology-driven education... Read more.
Encare’s ERAS® Interactive Audit System (EIAS) Earns Qualification on Mayo Clinic Platform
STOCKHOLM, Aug. 26, 2025 /PRNewswire/ — Encare AB today announced that its ERAS® Interactive Audit System (EIAS) has been qualified as a solution on Mayo... Read more.
Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT® in brain cancer patients
Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight’s treatment platform. Initiation... Read more.
Notification of Non-Compliance from Nasdaq
BEIJING, Aug. 26, 2025 /PRNewswire/ — CIMG Inc. (“CIMG” or the “Company”) (Nasdaq: IMG), a business group specializing in digital health... Read more.